Esmethadone hydrochloride is a Small Molecule owned by Relmada Therapeutics, and is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing.

REL-1017 (D-methadone) is N-methyl-D-aspartate receptor antagonist. NMDA receptor antagonists reduce hyperalgesia and allodynia of neuropathic pain induced by nerve injury. Pain is mediated in part by the excitatory amino acids glutamate and aspartate binding to the N-methyl-D-aspartate (NMDA) receptor. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain and reduced functionality of opioid receptors. D-Methadone antagonizes the action of stimulated NMDA receptors and thereby checks the CNS activity.

The revenue for Esmethadone hydrochloride is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Esmethadone hydrochloride NPV Report.

Esmethadone hydrochloride is currently owned by Relmada Therapeutics.

Esmethadone hydrochloride Overview

REL-1017 (D-methadone) is under development for the treatment of major depressive disorder, treatment resistant depression. The drug candidate is administered through oral route as a solution and tablet. The drug candidate is a nonopioid analgesic which acts by targeting N-methyl-D-aspartate (NMDA) receptor. It is a d optical isomer of racemic methadone. It is a new chemical entity.

It was also under development for the treatment of post herpetic neuralgia, Rett syndrome, ophthalmology, mitochondrial diseases, amyotrophic lateral sclerosis, substance (drug) abuse and neuropathic pain and restless leg syndrome.

Relmada Therapeutics Overview

Relmada Therapeutics, formerly Camp Nine, is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product esmethadone is used for the treatment of central nervous system (CNS) diseases and other disorders. It conducts various phases of clinical trials like Phase I and II. The company also carries out research and development. Relmada Therapeutics is headquartered in Coral Gables, Florida, the US.

The operating loss of the company was US$125.7 million in FY2021, compared to an operating loss of US$60.8 million in FY2020. The net loss of the company was US$125.8 million in FY2021, compared to a net loss of US$59.5 million in FY2020.

Quick View – Esmethadone hydrochloride

Report Segments
  • Innovator
Drug Name
  • Esmethadone hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
  • Ophthalmology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.